Four Hot Topics

11 REMISSION AND LOW DISEASE ACTIVITY: THE NEW TARGETS FOR TREATMENT

George Bertias. *University of Crete Medical School, Greece*

10.1136/lupus-2020-la.11

In chronic inflammatory diseases such as rheumatoid arthritis, attainment of a specific cut-off of low (or even absent) disease activity has been associated with favourable long-term disease outcomes. Systemic lupus erythematosus (SLE) is a complex, systemic disease where prognosis is determined by a variety of factors including disease activity and exposure to potentially toxic drugs particularly glucocorticoids. To this end, both increased activity (either persistent or exacerbations following a period of inactivity) and continuous intake of prednisone at doses above 5–7.5 mg/day have been correlated with accrual of irreversible dysfunction or damage in a variety of organs.

Delineation of the optimal therapeutic goal in SLE is challenging, which is in part due to the inherent limitations of the available clinical instruments for monitoring the disease. Nonetheless, through an evidence- and consensus-based approach, an international expert panel has recently introduced various definitions of remission in SLE¹ namely: (a) complete remission (with normal serological markers); (b) clinical remission (irrespective of serological markers); (c) complete remission on-treatment (allowing intake of stable maintenance immunosuppressives and/or ≤ 5 mg/day of prednisone); and (d) clinical remission on-treatment. In the aforementioned definitions, remission is established by combination of absent disease activity (typically, SLEDAI=0 and physician-rated global disease activity [physician global assessment-PhGA] ≤ 0.5). In addition, an Asia-Pacific collaborative group has proposed lupus low disease activity state (LLDAS)² as minimally acceptable disease activity (including serological markers and allowing intake of stable maintenance immunosuppressives and/or ≤ 7.5 mg/day of prednisone) in patients with SLE. A SLEDAI cut-off of ≤ 4 with PhGA of ≤ 1 are included in this definition. Accordingly, a number of observational studies have shown that attainment of either remission or LLDAS is associated with improved patient outcomes such as prevention of flares and organ damage accrual.^{3,4}

However, a number of issues pertaining to the definition of therapeutic target in SLE require clarification. First, although PhGA is useful in monitoring the disease by acting as a 'safety net' against the drawbacks of SLEDAI, it is still subject to inter-rater variability.⁵ Second, existing definitions of remission and LLDAS comprise of a combination of features such as an objective activity index, physician-rated activity and dose of glucocorticoids. The extent to which all these components are prognostically important is not clear and recent studies suggest that SLEDAI=0 alone may suffice for the definition of remission in SLE.⁶ Finally, it has been a matter of debate whether serology (serum C3/C4, anti-dsDNA) should be included in the definition of treatment targets (remission, LLDAS) or whether the latter should be based on the clinical parameters of SLE activity. This is due to the lack of absolute concordance between clinical and serological activity and the fact, that most patients with stable abnormal serology have favourable long-term prognosis. Further studies in large, well-characterised patient registries will be required to address the

abovementioned issues, thus defining the optimal treatment goal in the disease.

Learning Objectives

- Identify factors with an adverse impact on organ damage accrual in patients with SLE
- Demonstrate understanding of the existing definitions of remission and low disease activity state in SLE
- Discuss unresolved issues related to the definitions of remission and low disease activity and their implementations in clinical practice

REFERENCES

1. van Vollenhoven R, Voskuyl A, Bertias G, *et al.* A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). *Ann Rheum Dis* 2017;**76**(3):554–61.
2. Franklin K, Lau CS, Navarra SV, *et al.* Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). *Ann Rheum Dis* 2016;**75**(9):1615–21.
3. Petri M, Magder LS. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. *Arthritis Rheumatol* 2018;**70**(11):1790–95.
4. Zen M, Iaccarino L, Gatto M, *et al.* Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. *Ann Rheum Dis* 2018;**77**(1):104–10.
5. Chessa E, Piga M, Arnaud L. Physician global assessment in systemic lupus erythematosus: can we rely on its reliability? *Ann Rheum Dis* 2020 doi: 10.1136/annrheumdis-2020-217632
6. Saccon F, Zen M, Gatto M, *et al.* Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. *Ann Rheum Dis* 2020 doi: 10.1136/annrheumdis-2020-217070 [published Online First: 2020/04/24].

12 BELIMUMAB HELPS LUPUS PATIENTS TO ACHIEVE LUPUS TARGETS

Andrea Doria. *University of Padova, Italy*

10.1136/lupus-2020-la.12

Remission and low disease activity (LDA) are the most important targets to achieve in systemic lupus erythematosus (SLE) management.^{1–4} Belimumab is the only biologic drug approved for SLE and whether or not it can help lupus patients to achieve these targets is a critical question.

In a post-hoc analysis carried out in patients enrolled in BLISS-52 and BLISS-76, remission and LDA were able to discriminate response to belimumab 10 mg/kg from placebo.^{5,6} Notably, clinical (c) SLEDAI-2K=0 was the best discriminator⁶ and, importantly, in a recent multicentre cohort study including 646 patients, cSLEDAI=0 had the best performance in predicting damage accrual compared with all other definitions of remission.⁷

In real-life the proportion of patients who can achieve a stable low lupus disease activity state (LLDAS) and remission was higher than that obtained in randomised controlled trials, as shown in two recent studies.^{8,9}

A recent Italian multicentre cohort study of 466 patients on the use of belimumab in clinical practice settings, with a median follow-up of 18 months (range 1–60 months), showed that 71.7% of patients achieved LDA, 61.3% SRI-4, and 41.1% remission at 12 months, with these figures being maintained over time.¹⁰ The most important independent predictors of SRI-4 response were baseline SLEDAI2K ≥ 10 , SLE duration ≤ 2 years and a baseline SLICC damage index=0. Independent predictors of remission and LDA were baseline SLEDAI-2K < 10 , baseline SLICC damage index=0 and

prednisone intake ≤ 7.5 mg, and negative predictors of remission and LDA were number of flares in the 3 years before belimumab treatment initiation and baseline renal involvement. Notably, patients spending at least 50% of follow-up in LDA (66%) or at least 25% of follow-up in remission (42.9%) accumulated less damage at the end of the follow-up.

Consequently, this study provided novel evidence that an earlier use of belimumab in patients with active SLE and low damage may maximise its efficacy in clinical practice.

Learning Objectives

- Explain the importance of achieving remission or LDA in SLE management
- Describe the role of belimumab in achieving remission or LDA in post-hoc analysis of the randomised control trials
- Discuss the best use of belimumab in clinical practice settings

REFERENCES

1. Gatto M, Zen M, Iaccarino L, et al. New therapeutic strategies in systemic lupus erythematosus management. *Nat Rev Rheumatol* 2019;**15**(1):30–48.
2. Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. *Ann Rheum Dis* 2015;**74**(12):2117–22.
3. Zen M, Iaccarino L, Gatto M, et al. The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients. *Ann Rheum Dis* 2017;**76**(3):562–65.
4. Zen M, Iaccarino L, Gatto M, et al. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. *Ann Rheum Dis* 2018;**77**(1):104–10.
5. Oon S, Huq M, Golder V, et al. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. *Ann Rheum Dis* 2019;**78**(5):629–33.
6. Parodis I, Emamikia S, Gomez A, et al. Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. *Expert opinion on biological therapy* 2019;**19**(2):157–68.
7. Saccon F, Zen M, Gatto M, et al. Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. *Ann Rheum Dis* 2020;**79**(7):943–50.
8. Fanouriakis A, Adamichou C, Koutsoviti S, et al. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. *Semin Arthritis Rheum* 2018;**48**(3):467–74.
9. Sbeih N, Mathian A, Pineton de Chambrun M, et al. Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter. *Ann Rheum Dis* 2019;annrheumdis-2019-215732.
10. Gatto M, Saccon F, Zen M, et al. Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus. *Arthritis Rheumatol* 2020 doi: 10.1002/art.41253 [published Online First: 2020/04/11]

13

CAN WE WITHDRAW LOW-DOSE PREDNISONE IN REMITTED PATIENTS?

Zahir Amoura. Pitié-Salpêtrière University Hospital, Paris, France

10.1136/lupus-2020-la.13

Maintenance of remission has become central in the management of systemic lupus erythematosus (SLE). However, an active disease-free state is generally maintained only when patients are on medication, which often leads to treatment-related complications. Therefore, once remission has been achieved, prolonged maintenance treatment inevitably requires a regimen of drug de-escalation. The recent EULAR recommendations for the treatment of SLE during chronic maintenance treatment advocate that glucocorticoids (GC) should be, when possible, withdrawn.¹ However, in routine practice a significant proportion of treating physicians prefers to continue a low dose GC regimen, despite clinical

remission, which is most likely due to the fear that withdrawal of low-dose GCs may lead to a severe flare, even after very long intervals of remission.² In a recent prospective randomised controlled trial, we showed that, in SLE patients in remission and with stable treatment regimen for at least 1 year, withdrawal of 5 mg of prednisone was associated with a fourfold increase (i.e. 27%), in the risk of flare, as defined by the SFI or the BILAG index.³ Other SLE treatments remained unmodified during this study. In particular, at study entry 91% and 27% of the patients were also treated with hydroxychloroquine and an immunosuppressant, respectively. The 27% relapse rate observed in the withdrawal group in our study is in line with the ones recently reported in two recent cohorts.^{4 5} Tani *et al* described the longitudinal study of a cohort of 91 SLE Italian patients who attempted stopping GC treatment.⁴ A total of 77 patients successfully stopped GC. For those patients who were successfully withdrawn from GC, 18 flares (23%) were recorded after a median follow-up period of about 2 years. As in our study, 72% of flares were mild. The time period since the last flare was the sole determinant predictor of disease flare identified. A recent observational study, performed by Goswami *et al* in India, reported that 21% of patients in remission undergo exacerbation of the disease after GC withdrawal with most of the flares occurring in the first year of follow-up.⁵ Therefore, until the availability of effective drugs with little or no toxicity, it is recommended to not abandon the option of using very low doses of GCs (i.e. ≤ 5 mg prednisone) given their potential benefits in SLE patients in remission, especially those at low cardiovascular risk.

Learning Objectives

- Define remission in SLE patients
- Discuss drug de-escalation in SLE patients in remission

REFERENCES

1. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis* 2019;**78**(6):736–45.
2. Ngamjanyaporn P, McCarthy EM, Sergeant JC, et al. Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. *Lupus Sci Med* 2017;**4**(1):e000173.
3. Mathian A, Pha M, Haroche J, et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. *Ann Rheum Dis* 2020;**79**(3):339–46.
4. Tani C, Elefante E, Signorini V, et al. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience. *RMD open* 2019;**5**(2):e000916.
5. Goswami RP, Sit H, Ghosh P, et al. Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centre. *Clin Rheumatol* 2019;**38**(4):1089–97.

14

CAN WE WITHDRAW IMMUNOSUPPRESSANTS IN REMITTED PATIENTS?

Margherita Zen. University of Padova, Italy

10.1136/lupus-2020-la.14

Remission has recently emerged as a potential target in the management of systemic lupus erythematosus (SLE), indeed remission is not uncommon and is associated with improved prognosis.^{1 2} Nevertheless, the best management of remitted patients, especially those in stable remission, remains elusive. In particular, whether immunosuppressive therapy (IS) may be